Pillar I

AI-guided discovery of plant-derived therapeutic leads

Turning plant chemistry into testable drug leads, with an AI pipeline that narrows thousands of compounds down to the few worth testing.

Discovery funnel

1. Plant genetics and strains—

2. Chemistry and mass spectrometry—

3. ADME and toxicology prediction—

4. Target matching, docking and MD—

5. Retrosynthesis (Spaya, ChemAIRS, open tools)—

6. Lab screening—

7. Regulatory evidence (NDI / IND)—

What reviewers ask for is mapped back into the models, so missing evidence is flagged early.

From plant to molecule

Cannflavin A (example lead) · prenylated flavone

Scroll: plant → leaf → cell → molecule

Case study: cannabis flavonoids in oncology

Cannflavin A was screened in the National Cancer Institute's NCI-60 cell-line panel, with signals in glioblastoma, leukemia and melanoma lines. A follow-up multidose study was accepted.

Preclinical / lab

NCI-60 screen
Preclinical / lab
Dose-response
Proposed
Normal-cell selectivity
Proposed
Organoids
Proposed
Mechanism (e.g., RSK2 kinase)
Proposed
Safety
Proposed
Delivery
Proposed

Cell-line screening results are not clinical efficacy.

Mass spectrometry

A molecule fragments, the fragments land as peaks, and matches against the predicted spectrum light up.

Video coming soon

From plant to lead compound